These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26515981)

  • 21. An oldie but a goodie - cell wall biosynthesis as antibiotic target pathway.
    Schneider T; Sahl HG
    Int J Med Microbiol; 2010 Feb; 300(2-3):161-9. PubMed ID: 20005776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting a cell wall biosynthesis hot spot.
    Müller A; Klöckner A; Schneider T
    Nat Prod Rep; 2017 Jul; 34(7):909-932. PubMed ID: 28675405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LiaRS reporter assay: A simple tool to identify lipid II binding moieties in lantibiotic nukacin ISK-1.
    Elsayed KM; Islam MR; Abdullah-Al-Mahin ; Nagao JI; Zendo T; Sonomoto K
    J Biosci Bioeng; 2017 Mar; 123(3):398-401. PubMed ID: 27856233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colicin M, a peptidoglycan lipid-II-degrading enzyme: potential use for antibacterial means?
    Touzé T; Barreteau H; El Ghachi M; Bouhss A; Barnéoud-Arnoulet A; Patin D; Sacco E; Blanot D; Arthur M; Duché D; Lloubès R; Mengin-Lecreulx D
    Biochem Soc Trans; 2012 Dec; 40(6):1522-7. PubMed ID: 23176510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Found Hope for Antibiotic Discovery: Lipid II Inhibitors.
    Ng V; Chan WC
    Chemistry; 2016 Aug; 22(36):12606-16. PubMed ID: 27388768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies.
    Bonelli RR; Schneider T; Sahl HG; Wiedemann I
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1449-57. PubMed ID: 16569864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015.
    Deak D; Outterson K; Powers JH; Kesselheim AS
    Ann Intern Med; 2016 Sep; 165(5):363-72. PubMed ID: 27239977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting extracellular pyrophosphates underpins the high selectivity of nisin.
    Bonev BB; Breukink E; Swiezewska E; De Kruijff B; Watts A
    FASEB J; 2004 Dec; 18(15):1862-9. PubMed ID: 15576489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural Insights into the Mode of Action of the Peptide Antibiotic Copsin.
    Franzoi M; van Heuvel Y; Thomann S; Schürch N; Kallio PT; Venier P; Essig A
    Biochemistry; 2017 Sep; 56(37):4992-5001. PubMed ID: 28825809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural insights into inhibition of lipid I production in bacterial cell wall synthesis.
    Chung BC; Mashalidis EH; Tanino T; Kim M; Matsuda A; Hong J; Ichikawa S; Lee SY
    Nature; 2016 May; 533(7604):557-560. PubMed ID: 27088606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural variations of the cell wall precursor lipid II in Gram-positive bacteria - Impact on binding and efficacy of antimicrobial peptides.
    Münch D; Sahl HG
    Biochim Biophys Acta; 2015 Nov; 1848(11 Pt B):3062-71. PubMed ID: 25934055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dalbavancin approved for acute skin infections.
    Traynor K
    Am J Health Syst Pharm; 2014 Jul; 71(13):1062. PubMed ID: 24939490
    [No Abstract]   [Full Text] [Related]  

  • 34. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
    Roberts KD; Sulaiman RM; Rybak MJ
    Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial Agents.
    Hahn AW; Jain R; Spach DH
    Med Clin North Am; 2016 Jul; 100(4):911-26. PubMed ID: 27235621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total Synthesis of Laspartomycin C and Characterization of Its Antibacterial Mechanism of Action.
    Kleijn LH; Oppedijk SF; 't Hart P; van Harten RM; Martin-Visscher LA; Kemmink J; Breukink E; Martin NI
    J Med Chem; 2016 Apr; 59(7):3569-74. PubMed ID: 26967152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dalbavancin: a review.
    Scheinfeld N
    Drugs Today (Barc); 2007 May; 43(5):305-16. PubMed ID: 17724497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential inhibition of Staphylococcus aureus PBP2 by glycopeptide antibiotics.
    Leimkuhler C; Chen L; Barrett D; Panzone G; Sun B; Falcone B; Oberthür M; Donadio S; Walker S; Kahne D
    J Am Chem Soc; 2005 Mar; 127(10):3250-1. PubMed ID: 15755121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Origin, structure, and activity in vitro and in vivo of dalbavancin.
    Malabarba A; Goldstein BP
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii15-20. PubMed ID: 15750032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.